Abstract. The human lymphocyte homing receptor LAM-1, like its murine counterpart MEL-14, functions as a mammalian lectin, and mediates the binding of leukocytes to specialized high endothelial cells in lymphoid organs (HEV) . LAM-1 is a member of a new family of cell adhesion molecules, termed selectins or LEC-CAMs, which also includes ELAM-1 and PAD-GEM (GMP-140/CD62) . To localize the regions of LAM-1 that are involved in cell adhesion, we developed chimeric selectins, in which various domains of PAD-GEM were substituted into LAM-1, and used these chimeric proteins to define the domain requirements for carbohydrate binding, and to localize the regions recognized by several mAb which inhibit the adhesion of lymphocytes to lymph node HEV. The binding of PPME or fucoidin, soluble complex carbohydrates that specifically define the lectin activity of LAM-1 and MEL-14, required only the lectin domain of LAM-1. The LAMM, LAMI-3, and LAMI-6 mAb each strongly inhibit the T HE interaction of circulating leukocytes with vascular endothelium underlies a number of phenomena important to host defense. The recirculation oflymphocytes throughout the secondary lymphoid organs, a process which is necessary to ensure that the full complement of antigen receptors is available throughout the organism, and the recruitment of leukocytes to sites of inflammation, are each regulated principally at the level of binding of leukocytes to specially modified regions of the vessel wall. A number of leukocyte and endothelial cell surface molecules that participate in this process have been identified and characterized in both mouse and man . Among the best characterized ofthe leukocyte receptors is the murine lymph node homing receptor 24, 31) , and its human counterpart, the leukocyte adhesion molecule-1 (LAM-1) (21, 42, 43) , which mediate the binding of lymphocytes to the specialized high walled endothelium in the postcapillary venules present in most secondary lymphoid organs (high endothelial venules or HEV) .' (LAM-1 is recognized by the Leu-8, TQI, and 1. Abbreviations used in this paper: HEV, high endothelial venules; PCR, polymerase chain reaction ; SCR, short concensus repeat .
T HE interaction of circulating leukocytes with vascular endothelium underlies a number of phenomena important to host defense. The recirculation oflymphocytes throughout the secondary lymphoid organs, a process which is necessary to ensure that the full complement of antigen receptors is available throughout the organism, and the recruitment of leukocytes to sites of inflammation, are each regulated principally at the level of binding of leukocytes to specially modified regions of the vessel wall. A number of leukocyte and endothelial cell surface molecules that participate in this process have been identified and characterized in both mouse and man . Among the best characterized ofthe leukocyte receptors is the murine lymph node homing receptor MEL-14 (10, 24, 31) , and its human counterpart, the leukocyte adhesion molecule-1 (LAM-1) (21, 42, 43) , which mediate the binding of lymphocytes to the specialized high walled endothelium in the postcapillary venules present in most secondary lymphoid organs (high endothelial venules or HEV) .' (LAM-1 is recognized by the Leu-8, TQI, and binding of lymphocytes to HEV in the in vitro frozen section assay, and defined three independent epitopes on LAM-1. Blocking of PPME or fucoidin binding by LAMI-3 indicated that this site is identical, or in close proximity, to the carbohydrate binding site, and analysis of the binding of LAMI-3 to chimeric selectins showed that the epitope detected by LAMI-3 is located within the lectin domain . Although the LAMI-6 epitope is also located in the lectin domain, LAMI-6 did not affect the binding of PPME or fucoidin . The LAMl-1 epitope was located in, or required, the EGF domain, and, importantly, binding of LAMl-1 significantly enhanced the binding of both PPME and fucoidin. These results suggest that adhesion mediated by LAM-1 may involve cooperativity between functionally and spatially distinct sites, and support previous data suggesting a role for the EGF domain of LAM-1 in lymphocyte adhesion to HEV DREG series mAb, in addition to the ones described in this report, and has also been referred to as LEC-CAM-1 and LECAM-1 .) These molecules are also expressed on other classes of leukocytes, including neutrophils and monocytes (13, 19, 43) , and recent evidence suggests a role for LAM-1/ MEL-14 in the recruitment ofleukocytes to inflammatory lesions (18, 25, 47) . In man, LAM-1 is also expressed on the majority ofcirculating hematopoietic stem cells (13) , raising the possibility that this molecule is also involved in stem cell traffic.
A diverse array of functional evidence has clearly demonstrated that these homing receptors function as mammalian lectins . Thus, binding of lymphocytes to LN HEV, but not Peyer's patch HEV, is specifically inhibited by certain simple sugars, including mannose-6-phosphate (M6P) andthe structurally related fructose-l-phosphate, by PPME, a M6P-rich mannan core from the yeast Hansenula holsdi, and by fucoidin, a fucose-rich polysaccharide (38-40, 48, 49) . PPME and fucoidin bind specifically to LAM-1 and MEL-14, and this binding is inhibited by some antibodies that selectively bind to these HEV receptors and thereby inhibit the binding oflymphocytes to LN HEV (21, 34, 48) . Inaddition, thebind-ing of PPME or fucoidin to LAM-1 or MEL-14 and of lymphocytes to LN HEV exhibits an identical absolute requirement for Caz+ (37, 40) . The lectin activity of MEL-14 has recently been directly confirmed using purified MEL-14 protein (15) . These data have firmly established an essential role for specific recognition ofcarbohydrate in adhesion mediated by this class of cell adhesion molecules .
Molecular cloning of MEL-14 (24, 31) and LAM-1 (3, 6, 30, 42) has recently revealed that these molecules are members of a larger family of cell adhesion molecules . Termed LEC-CAMs (36) or selectins (11, 35) , this family also includes ELAM-1, which is expressed on cytokine treated endothelium and mediates the binding ofleukocytes, principally neutrophils, to these cells (1, 2) ; and PADGEM (GMF140, CD62), which is expressed on activated platelets and endothelium, and mediates the binding of these cells to monocytes and neutrophils (11, 16, 22) . Selectins are characterized by a novel arrangement of distinct protein motifs, the most prominent of which is an amino-terminal C-type lectin domain, consistent with the functional evidence described above. This is followed by a domain homologous to EGF, a variablenumber (twoinLAM-1 and MEL44, six in ELAM-1, and nine in PADGEM [36] ) of tandem repeats homologous to complementregulatory proteins, a transmembrane region, and a cytoplasmic tail. Although the presence of a C-type lectin domain in these molecules is an elegant confirmation of the functional data described above, the function of these various domains in the adhesive or other biological properties of the selectins remains incompletely understood .
A requisite role for activation of adhesion molecules in efficient cell adhesion has been suggested by studies of several members of the integrin family (9, 29, 35) . Consistent with this hypothesis, we have recently shown that activation ofleukocytes induces a rapid and transient increase in adhesion mediated by LAM-1, and that this enhancement involves an increase in affinity of LAM-1 for carbohydrate (34) . In this study, we have used chimeric selectins, in which various regions of PADGEM have been substituted for those of LAM-1, to define the domains responsible for carbohydrate binding by LAM-1, and to identify other regions of the LAM-I molecule involved in cell adhesion and receptor regulation . The results suggest that LAM-1-mediated adhesion may involve the coordinated action of multiple sites withi the molecule, not all ofwhich are directly involved in carbohydrate recognition.
Materials and Methods

Production ofmAb to LAM-1
The production and detailed characterization of the anti-LAM-1 mAb used in this report will be described elsewhere (34a) . Briefly, the 300.19 munne pre-B cell line was transfected with LAM-1 eDNA (42) and used to immunize mice, as described (43) . Antibodies that stained the LAM-transfected but not the parent cell line were subeloned and analyzed further. This report uses three such mAbs, termed LAMI-1, LAMi-3, and LAMi-6.
Effect ofAnti-LAM-1 mAb on Binding ofPPME or Fucoidin
Peripheral blood lymphocytes were isolated by Ficoll-hypaque gradients. The cells were incubated on ice for 15 min in PBS containing 1% FCS and excess amounts of unlabeled antibody in the form of diluted ascites, and either PPME-FITC or facoidin-FITC, prepared as described (12) , was
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Construction of Chimeric Selectins
Four new restriction endonuclease recognition sites were introduced separately into the pLAM-1 eDNA (42) by polymerase chain reaction (PCR)-based site-directed mutagenesis as follows. Oligonucleotides surrounding and including each new restriction sequence were synthesized in both the sense and antisense directions. PCR was carried out using the new restriction site sense oligonucleotide + an antisense oligonucleotide anchor located in the plasmid near the 3' end of the eDNA . In a separate reaction, the new restriction site antisense oligonucleotide plus a sense oligonucleotide anchor from the plasmid 5' end were used to amplify the 5' end of the LAM-1 eDNA . The individual PCR products from these two reactions were gel purified, subeloned into the pSP65 vector (Promega Biotec, Madison, WI), digested with the appropriate restriction enzymes, and ligated together. The nucleotide changes were as follows: (a) GA361ATCC to GGATCC in the lectin domain, creating a BamHl site, corresponding to amino acid number 53 in the mature protein (42); (b) A583TGCAG to CTOCAG in the EGF domain, creating a Psd site, corresponding to amino acid number 127; (c) GAGGssICss 2C to GAGCTC in the first SCR domain, creating a Sacl site, corresponding to amino acid number 164 ; and (d) GTCAAA 1023 to GTCAAC in the second SCR domain, creating a Hincll site, corresponding to amino acid number 279 (Fig. 1 ) . The fidelity of the site-directed mutagenesis was confirmed by restriction mapping and sequence analysis of the cDNAs . Each of these sites is naturally present in the PADGEM eDNA (23) . Chimeric selectins were created by exchanging the indicated regions of LAM-1 and PADGEM ( Fig . 1) . Creation of the Sacl site involved a substitution of leu for ala ; creation of the HincIl site involved a substitution of thr for asn. These amino acid changes did not affect the level of expression of the mutants as detected by transient transfection in COS cells (data not shown) .
Domain Mapping of Binding Sitesfor PPME, Fucoidin, and mAb to LAM-1
The chimeric selectin cDNAs were subeloned into the APTm8 expression vector and transient transfection of COS cells was performed by the DEAE dextran method . 1 d after transfection, COS cells were replated onto plastic microscope coverslips. On day 2 after transfection, COS cells were incubated at room temperature for 30 min in humidified chambers with mAb to LAM-1 in the form ofascites fluid diluted in PBS/1% FCS, gently washed with PBS/1% FCS, and incubated similarly with fluoresceinated goat antibody to mouse Ig (Tago Inc ., Burlingame, CA) . For carbohydrate binding studies, a similar procedure was followed, except that PPME-FiTC or fucoidin-FITC were used . The cells were then mounted in Fluoromount-G (Fisher-Biotech, Pittsburgh, PA), and examined by fluorescence microscopy. Staining was considered positive only if clear membrane staining outlining the cell was seen. Scoring was as follows : 0, no staining ; +, 2-10%+ ; ++, 10-25 % + ; +++, 25-50 % + ;++++, >50% + . Negative controls included transfection of COS cells with vector alone, vector with irrelevant eDNA (e .g., CD19) (41) , and staining with ascites of irrelevant specificity, and these samples always exhibited t1 % staining. Expression of LIP, which is not detected by any offourteen anti-LAM-1 mAb examined, was confirmed by staining with the AC1 .2 (22) and/or KC4 (14) anti-PADGEM mAbs .
Results
Construction ofLAM11PADGEM Chimeric cDNAs
To identify the regions of LAM-1 involved in cell adhesion, and to determine the site and domain requirements ofcarbohydrate binding, we constructed chimeric selectin cDNAs by substituting homologous regions of PADGEM into LAM-1 . Novel restriction sites were introduced into the pLAM-1 eDNA (42) by PCR-based site-directed mutagenesis . Chimeric selectin cDNAs containing the 5' half of the lectin domain of LAM-1 (designated LIP), the entire lectin domain (UP), the lectin plus EGF domains (UP), or nearly the entire extracellular portion (LAP) of LAM-1, with the remainder of the cDNA as PADGEM, were constructed (Fig.  1) . In addition, a LAM-1 cDNA with only the EGF domain of PADGEM substituted for that of LAM-1 was constructed (L2P3L). Chimeric selectin cDNAs with PADGEM at the 5' end and LAM-1 at the 3' end were also constructed, but were not expressed at detectable levels in COS cells. Because the PADGEM and LAM-1 proteins share an identical domain orization (36), thesechimeric molecules are likely to retain erall topology of the parent molecules. This approach to analyzing functional domains has many advantages over deletion analysis, which may change the conformation of the resulting molecules in unpredictable ways .
Binding ofPPME or Fucoidin Requires only the Lectin Domainfrom LAM-1
The chimeric selectins were subcloned into the Aprm8 COS cell expression vector and analyzed for carbohydrate binding in transient transfection assays . Both PPME and fucoidin bound to UP, which contains the entire lectin domain of Kansas Restriction sites were introduced separately into the LAM-1 cDNA as described in detail in Materials and Methods (bold arrows at top) . The leader (L), lectin, EGF, SCR, transmembrane (TM), cytoplasmic (C), and 3' untranslated (3'UT) domains are indicated . LAM-1 regions are in white, and those derived from PADGEM are shaded . The double slash in the PADGEM SCR region is to indicate that PADGEM has nine SCR repeats (unlike LAM-1, which has two), and all of them are included in LIP, UP, and UP.
LAM-l, but not to PADGEM, or to LIP, which contains only the 5' half of the lectin domain (Table I and Fig . 2) . At least part of the binding site for these carbohydrates is therefore located in, or requires, the 3' half of the lectin domain . In addition, binding of both PPME and fucoidin to UP was equivalent to or better than binding to LAM-1, or to UP or L4P, which contain the lectin + EGF of LAM-1 and the lectin + EGF + short concensus repeat (SCR) domains of LAM-1, respectively (see Fig . 1 ) . These data indicate that the EGF and SCR domains of PADGEM can replace those of LAM-1 without affecting the binding of PPME or fucoidin, and therefore, that these domains of LAM-1 are not required for carbohydrate recognition and binding. Domain Mapping of theBinding Sites ofLAMI1, LAMI-3, and LAMI-6 mAb As described in detail elsewhere (34a), the LAMI-1, LAMI-3, and LAMI-6 mAb each strongly inhibit the binding of lymphocytes to lymph node HEV in the frozen section assay, and define three spatially distinct epitopes on the LAM-1 molecule. To identify the domain locations of the epitopes defined COS cells transfected with LAM-1, PADGEM, or the chimeric selectin cDNAs were analyzed in transient transfection assays for staining with the indicated carbohydrates or mAb, as described in Materials and Methods . PPME, fucoidin, LAMI-3, and LAM 1-6 recognized the lectin domain of LAM-1, whereas LAMIA expression was absent in chimeras lacking the LAW EGF domain . e of binding of carbohydrate or anti-LAM-1 monoclonal antibody to chimeric selectins. UP cDNA was expressed OS cells, and binding of mAb or carbohydrate was assessed as described in Materials and Methods . A-C, phase contrast; D-F, fluscence (FIT'C) . A and D, negative control; B and E, staining with LAMI-3 ; C and F, staining with PPME-FIT'C . Bar, 10 Am.
by these mAb, we analyzed the chimeric selectins as described above. Similar to PPME and fucoidin, LAMI-3 and LAMI-6 stained COS cells transfected with UP, UP, LAP, and LAM-l, but not COS cells transfected with UP or PAD-GEM (Table I and Fig. 2) , indicating that at least part of the epitopes defined by these mAb are also located in, or require, the 3' half of the lectin domain. Because LAMI-3 and LAMI-6 do not cross-block each others binding to of Cell Biology, Volume 114, 1991 LAM-1 (34a), this demonstrates that LAMI-3 and LAMI-6 identify two distinct functional epitopes within the lectin domain. In contrast, binding of LAMI-1 was not detected in chimeras lacking the LAM-1 EGF domain (Table 1) , indicating that the LAMl-1 epitope is within (or requires) the EGF domain. In combination with the observation that both PPME and fucoidin bind to chimeric selectins lacking the LAM-1 EGF domain, these data suggest that the LAMI-1 mAb, which inhibits lymphocyte/HEV binding, recognizes a domain of LAM-1 which is not required, i.e., can be replaced with that of PADGEM, for binding of PPME or fucoidin .
LAMI1, LAW-3, and LAMI-6 Have Distinct Effects on Carbohydrate Binding
To directly relate the functional epitopes defined by these mAb to the carbohydrate binding site, the effect of mAb binding on the binding of PPME and fucoidin was assessed . Peripheral blood lymphocytes were incubated with three-to fivefold excess concentrations of each of these three mAbs, followed by PPME-FITC or fucoidin-FITC, and analyzed by flow cytometry. Prior incubation of cells with LAMI-3 completely blocked the binding of both PPME-FITC and fucoidin-FITC (Fig . 3) , suggesting that the LAMI-3 epitope is at or in close proximity to the carbohydrate binding site. In contrast, LAMI-6, which also strongly inhibits lymphocyte binding to HEV (34a) and also maps to the lectin domain (Table I) , had little or no effect on carbohydrate binding. Surprisingly, the binding of LAMI-1 significantly enhanced the binding of both PPME and fucoidin (Fig . 3) , an effect which varied 4-10-fold over several experiments. This enhanced binding was also inhibited by the LAMI-3 mAb or EDTA (data not shown), indicating that this increased level of carbohydrate binding was also LAM-1 dependent. Thus, a mAb with antagonist activity in one functional assay of LAM-1 had agonist activity in a separate LAM-1 functional assay.
Discussion
The genetic mapping of functional domains of a number of proteins that are members of gene families has been facilitated by theconstruction and analysis of chimeric molecules, in which different regions of one family member are exchanged for the corresponding regions of a different member of the same family. Unlike deletion analysis, in which portions of a molecule are simply removed, this approach preserves the overall topology of the protein, thus preserving some of the biological properties of the parent molecules. In this report, we have used chimeric selectins to localize the carbohydrate binding site within LAM4, and to locate the epitopes identified by three mAb which inhibit lymphocyte binding to HEV.
Our results directly demonstrate that binding of PPME or fucoidin by LAM-1 requires only the lectin domain of LAM-1, and therefore suggest that the carbohydrate binding site is contained within the lectin domain . The selective inhibition of carbohydrate binding by LAMI-3 mAb (Fig. 3) suggests that this antibody binds at or near the carbohydrate binding site, as definedby PPME and fucoidin . These results also demonstrate that neither the EGF nor SCR domains of LAM-1 are necessary for carbohydrate binding, i .e., that the EGF and SCR domains of PADGEM, which does not bind PPME or fucoidin in these assays (Table I) , can subserve whatever role, if any, is played by these domains with respect to carbohydrate binding. These domains therefore probably do not play an important role in determining the specificity of carbohydraterecognition . These resultsdo not, however, exclude an essential structural role for the EGF domain in ensuring a proper conformation for the lectin domain, as is suggested by the observation that the EGF domains of MEL-14 and LAMI-6 ; (I and J) LAMM . LAMI-3 blocks, LAMI-1 enhances, and LAMI-6 has no effect, on the binding of both PPME and fucoidin .
ELAM-1 were necessary to preserve epitopes identified by the MEL-14 and H18/7 mAb, respectively (4, 45) . That the EGF domain of PADGEM can substitute for that of LAM-1 indicates that the structural features of the EGF domain, which are apparently essential for lectin domain function, have been well conserved among the selectins.
The LAMI-3 antibody resembles the MEL-14 antibody in its inhibition of both PPME and lymphocyte/HEV binding, and in the localization of its binding site to the lectin domain (4, 10, 48) . The observation that PPME, fucoidin and LAMI-3 each bind to L2P, which contains the entire lectin domain of LAM-1, but not to LIP, which contains only the amino-terminal 53 amino acid residues of LAM-1, suggests that at least part of the carbohydrate/LAMI-3 binding site is in the carboxy-terminal -67 amino acids of the lectin domain . Although these results would appear to differ from those of Bowen et al ., who used MEL-14/LAM-1 chimeras to deduce that at least part of the epitope for the MEL-14 antibody is located in the amino-terminal 53 amino acids of the lectin domain (4), the strong homology between the selectins, and the absolute conservation of the cysteine residues in the lectin and EGF domains, suggests that both the MEL-14 and LAMI-3 epitopes are actually conformationally determined epitopes formed by residues present in both "halves" of the lectin domain, and implies that the carbohydrate binding site shares a similar structural requirement . Inthis regard, a number of residues can be identified in the lectin domain that are shared by MEL-14 and LAM-1, but that are distinct for both ELAM-I and PADGEM, suggesting that some of these residues may be involved in specific recognition ofcarbohydrate, and thesepotential carbohydrate specificity determining residues are located largely unclustered throughout the lectin domain (Fig. 4 a) . A precedent for linearly noncontiguous residues of a protein comprising a carbohydrate binding site is the well characterized hemagglutinin of influenza virus (reviewed in reference 5) . Identification of the precise residues which are responsible for carbohydrate recognition and binding by these and other C-type animal lectins awaits further experimentation . The region defined by the LAMI-6 mAb, which, like the LAMI-3 mAb, inhibits lymphocyte adhesion to HEV, is also within the lectin domain (Table I ), but at a site spatially distinct from the LAMI-3/carbohydrate binding site. This suggests that two distinct regions within the lectin domain of LAM-1 are involved in lymphocyte adhesion to HEV. Although a number of structurally unrelated polysaccharides, including PPME, fucoidin, and sulfatide, can selectively and specifically inhibit lymphocyte adhesion to LN HEV (15) , it seems unlikely that the lectin domain recognizes two separate, distinct, and unrelated carbohydrates . Rather, it is more likely that each ofthese different reagents resembles the physiologic carbohydrate ligand or a component thereof, thereby allowing recognition by LAM-1/MEL-14 . Although the LAMI-6 mAb does not inhibit the binding of PPME or fucoidin (Fig. 3) , it remains possible that inhibition of HEV binding by LAMI-6 may be due to steric hindrance of lectin domain activity (i.e., recognition of carbohydrate) that is not detectable by analysis of PPME or fucoidin binding . In this regard, itshould be explicitly emphasized thatthe soluble carbohydrates used in these and other studies areunlikely to perfectly model the physiologic carbohydrate ligand. It is therefore possible that the effects ofmAb on the binding of PPME or fucoidin do not accurately predict the effect of these mAb on the recognition of the natural carbohydrate ligand by the lectin domain in the course of cell adhesion in vivo.
The LAMI-1 mAb also inhibits lymphocyte/HEV interactions, and the epitope defined by LAM1-1 is within, or requires, the EGF domain (Table I ). These properties are identical to what has been described for the Ly-22 mAb, which also recognizes the MEL-14 antigen (32) . The observation that this antibody enhances the binding of both PPME and fucoidin (Fig. 3) makes it less likely that inhibition of HEV binding by LAMI-1 is due to inhibition ofcarbohydrate binding. However, as indicated above, these data do not exclude the possibility that LAMW inhibits recognition of the natural carbohydrate ligand. It also seems unlikely that inhibition of HEV binding by LAMW is due to general allosteric effects, because the binding of the Leu-8 and LAMI-3 mAb, which identify distinct epitopes in the lectin domain (reference 45 and Table I) , is unaffected by LAMI-1 (34a and data not shown) . Moreover, with respect to carbohydrate binding, the EGF domain of LAM-1 can be replaced with that of PADGEM (Table I ). In addition, the degree ofamino acid identity between the EGF domains of the selectins is equal to that found in the lectin domains (63-67%) (Fig. 3  b) , suggesting an equally important role in the function of these molecules . Numerous examples of EGF-like domains mediating specific interactions between proteins exist (reviewed in reference 8) . These observations are consistent with the existence ofa second binding site, which is essential for lymphocyte binding to HEV, within the EGF domain.
A binding mechanism which involves interaction at two sites might be advantageous for several reasons . Suchamechanism might plausibly be expected to confer a high degree of specificity on the adhesive event . This consideration appears particularly relevant, given recent evidence indicating thatthe carbohydrate ligands ofthe selectins are closely structurally related : each contains sialic acid, and the ELAM-1 and PADGEM carbohydrate ligands include the sLex and Lex structures, respectively (7, 23, 26, 27, 28, (44) (45) (46) . Binding via two sites, especially ifcooperative, would also be expected to generate an interaction of higher avidity, which would be important given the apparently low affinity of LAM-1 for PPME or fucoidin, of PADGEM for CD15/ LNFIII/Lex, and of ELAM-1 for sLex (23, 26, 45) . In addition, a requirement for dual recognition of separate ligand components would allow the use of a limited number of carbohydrates and EGF-like domains to generate a larger number of specificities, thus obviating the need to evolve a large number of lectin domains . This last consideration may partially account for the unique mosaic ofprotein motifs characteristic of the selectins.
The unanticipated enhancement of carbohydrate binding by prior binding ofLAMM mAb raises interesting questions regarding the nature of receptor/ligand interactions . We have previously shown that activation of T cells by cross-linking CD3/TCR or CD2, or neutrophils by GM-CSF or TNF-«, leads to a rapid and transient upregulation ofPPME binding activity by a mechanism which involves the upregulation of affinity of LAM-1 for ligand (34) . This enhanced binding of PPME is indistinguishable from that produced by binding of LAM1-1 mAb. Taken together, these observations suggest that the EGF domain may be involved in the regulation of receptor function, including the increase inaffinity ofLAM-1 for carbohydrate associated with cellular activation.
The role ofthe SCR domains in the function of LAM-1 and the other selectins remains undefined . Our findings suggest that this region is not directly involved in cell adhesion, and therefore suggest that the SCR domains subserve primarily a structural requirement, perhaps by extending the adhesive domains sufficiently far from the glycocalyx to ensure efficient cell adhesion . This is consistentwiththe variablenumber ofSCR domains found in the different selectins, and with the lower degree of conservation exhibited by SCR domains compared with the other regions of these adhesion proteins. In the case ofLAM-1 and MEL-14, this region may also be involved in the shedding of the molecule associated with cellular activation (17, 20, 33, 43) .
In summary, we have demonstrated that antibodies to LAM-1 that inhibit lymphocyte adhesion to HEV have contrasting effects on the ability of LAM-1 to recognize PPME and fucoidin, soluble carbohydrates which bind to LAM-1 and inhibit adhesion to LN HEV. In addition, we have shown that these antibodies identify distinct regions in different domains of the molecule. Our findings therefore reinforce data indirectly suggesting a role for the EGF domain in cell adhesion (32) . Whether the EGF domain plays a role in supporting the appropriate conformation of the lectin domain, as suggested (4), participates directly in cell adhesion, or plays some other, unexpected role, awaits further investigation . Analysis of the ability of the chimeric selectins described in this paper to confer HEV binding, currently in progress, may provide a more definitive answer to this question .
